 --Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular inflammation or choroidal neovascularization-- --The serum pharmacokinetics PK of NGM621 were linear and dose-proportional-- 